CLINICAL EVALUATION OF THE BENEFITS OF TOPICAL CALCIUM HYDROXYAPATITE IN PATIENTS WITH SEVERE WEIGHT LOSS DUE TO GLP-1 AGONISTS: AN INTERVENTION STUDY WITH MULTILAYER ANALYSIS ASSOCIATED WITH DERMOCOSMETICS AND NUTRACEUTICALS

Background: The increasing use of GLP-1 receptor agonists for weight management has produced a new clinical profile of patients who present with significant weight loss (≥ 30 kg) accompanied by significant complaints of facial and body sagging, aggravated by the rapid reduction of adipose tissue and collagen loss induced by accelerated lipolysis. In response to this demand, this study evaluates the effects of topical calcium hydroxyapatite (topical CaHA) associated with a sequential protocol consisting of: (a) in-salon application with activation massage, (b) daily home care, (c) nutraceutical supplementation for metabolic and structural support. The sample was evaluated at two time points: T0 (baseline) and T15, using a facial analyzer with 8 photospectral images and epidermal and dermal skin readings, which allows analysis of 17 facial markers including: dermal thickness, texture, porosity, sagging, photodamage, blemishes, hydration, microvasculature, and volumetric aging. Objective: The aim of this study is to demonstrate the benefits of topical CaHA in stimulating superficial neocollagen, improving skin firmness, and tissue remodeling in patients undergoing rapid weight loss with GLP-1, as well as to understand the synergistic contribution of home care and nutraceuticals in the tissue recovery process. Conclusion: In summary, this study confirms that topical CaHA is a safe, non-invasive, and clinically relevant resource for minimizing accelerated aging and reducing skin damage in individuals who have undergone significant weight loss. Its application integrated with dermocosmetic and nutraceutical care represents a promising strategy for optimizing the structural and functional recovery of the skin in the post-weight loss context.